Impact of US Executive Order on Indian Generic Drugmakers

Cipla MD Umang Vohra assured that the US government's directive to lower prescription drug costs will not impact Indian generics, focusing instead on branded drugs. The Executive Order signed by President Trump aims to reduce costs through voluntary compliance and ties US prices to international rates.

Cipla's Managing Director and Global CEO, Umang Vohra, confirmed that the recent US directive to pharmaceutical companies to reduce prescription drug costs within 30 days will unlikely affect Indian generic manufacturers. Vohra emphasized that the measure targets branded drugs rather than generic ones.

Signed by President Donald Trump, the Executive Order sets a deadline for drug price reductions, intending to align US prices with those of other countries. Vohra mentioned that there are uncertainties regarding the order's implementation and its specific focus on branded medications.

Despite potential tariff implications on pharmaceutical imports, Vohra assured that Cipla's operations remain unaffected as they primarily produce generics, offering affordable medicines globally. The Executive Order continues to focus on international pricing strategies without directly impacting the generics sector.

(With inputs from agencies.)